Deadpool Blend 30mg

Description

Product Specifications

• Product: Deadpool Blend 30mg
• Compound / formulation: Deadpool Blend
• Labeled blend composition: Cartalax 10mg + BPC-157 10mg + Thymosin Beta-4 10mg
• Labeled quantity / volume: 30mg total per vial
• Physical form: White lyophilized peptide powder
• Research focus: Tissue Repair Research, Inflammatory Signaling, Cellular Repair Research, Angiogenesis Research
• Available batch identifiers: Clear vial / dark-purple cap
• SKU: HOP-deadpool-blend-30mg
• Intended classification: Laboratory research only

Independent Laboratory Testing

Clear dark purple cap — Freedom Diagnostics, accession 2609170320

• Compounds reported: Cartalax, BPC-157, Thymosin Beta-4 confirmed
• Cartalax measured content: 10.59mg
• BPC-157 measured content: 11.98mg
• Thymosin Beta-4 measured content: 9.97mg
• Combined measured content: 32.54mg
• Purity: 99.37%
• Report date: September 19, 2026
• View laboratory report

House of Peptides maintains an established testing and sampling protocol with its suppliers. Under this agreed protocol, samples are randomly selected from a production batch and submitted for independent laboratory analysis.

The submitted samples are drawn from the same production batch as the corresponding inventory supplied to House of Peptides. This batch-based sampling approach provides analytical information associated with the production batch rather than individual testing of every vial.

House of Peptides may maintain inventory from multiple production batches of the same compound. Each Certificate of Analysis corresponds to its identified batch, which may be distinguished by cap color or lot designation. Orders are fulfilled on a first-in, first-out (FIFO) basis, so the batch supplied depends on available inventory at the time of fulfillment. Laboratory findings apply to the submitted samples from their respective batches, not to every individual vial.

Scientific Research Background

Deadpool Blend combines three peptides associated with different areas of tissue biology research.

Cartalax, also known as the AED peptide, is a short chain of three amino acids studied for its interactions with cells involved in cartilage development and maintenance. Researchers have investigated its influence on biological markers associated with cartilage formation, particularly in laboratory models of cellular aging.

BPC-157 is a synthetic peptide consisting of 15 amino acids. Experimental studies have examined its effects on tendon and ligament organization, blood vessel formation, and cellular responses following tissue injury. Much of this research has been conducted in animal models.

Thymosin Beta-4 is a naturally occurring 43-amino-acid peptide involved in cellular movement and organization. Researchers have studied its role in processes associated with tissue repair, inflammation, and the maintenance of cellular structure.

The scientific interest in this three-component blend comes from the different biological processes investigated for each peptide. However, their combined activity has not been established through controlled studies of this exact formulation.

Compound details

• Peptide lengths: Cartalax: 3; BPC-157: 15; Thymosin Beta-4: 43 amino acids
• Research classification: Multi-peptide connective tissue and cellular signaling research blend

Clinical Research Observations

Researchers have studied the individual peptides in Deadpool Blend to better understand how different tissues respond to injury and maintain their structure. Most of these studies have involved laboratory experiments or animals rather than human clinical trials.

1. What have BPC-157 experiments shown about connective tissue?

Tendons connect muscles to bones, making their strength and organization important measurements in injury research.

What researchers found: In a study involving rats with injured Achilles tendons, researchers observed differences in tendon strength, tissue organization, and movement compared with untreated animals.

The researchers also examined tendon-producing cells in laboratory experiments. They found that BPC-157 influenced how these cells responded to a substance that interferes with normal cell growth.

Why it matters: These findings contributed to scientific interest in how BPC-157 interacts with the tissues that connect muscles and bones. Animal tendon outcomes cannot be assumed to occur in people.

2. Why is thymosin beta-4 studied in tissue repair?

The cornea is the clear outer surface of the eye. Researchers have studied how it restores its protective surface after injury.

What researchers found: In a study involving mice with experimentally injured corneas—the clear outer surface of the eye—researchers observed that tissues treated with Thymosin Beta-4 restored their protective surface more quickly than untreated tissues.

The researchers also reported fewer inflammatory cells in the affected area.

These observations have contributed to scientific interest in how Thymosin Beta-4 interacts with cells involved in tissue repair and maintenance.

Why it matters: Corneal repair in mice does not establish effects in other tissues or in humans.

3. What is being investigated about Cartalax and cartilage?

Cartilage cushions and supports joints. Laboratory studies examine how cartilage-related cells develop and change.

What researchers found: Cartalax has been investigated in laboratory research involving cells associated with cartilage development and aging.

Researchers have examined how this short peptide influences cellular activity related to cartilage formation.

Cartilage provides cushioning and structural support in areas such as joints. These studies help scientists explore how peptides may interact with the processes involved in maintaining cartilage tissue.

Why it matters: Cell-level cartilage research does not demonstrate joint benefits in people.

4. Has the complete Deadpool Blend been clinically tested?

Studies of separate ingredients and studies of a finished blend answer different questions.

What researchers found: The studies described above examined individual peptides under different experimental conditions. Their findings do not establish that the complete Deadpool Blend produces equivalent results, additional effects, or clinical benefits in humans.

Why it matters: The finished blend has not been established as effective or safe in people from these individual studies.

Published Scientific Research

• Staresinic et al. (2003) — Gastric Pentadecapeptide BPC 157 Accelerates Healing of Transected Rat Achilles Tendon and In Vitro Stimulates Tendocytes Growth. Journal of Orthopaedic Research. https://doi.org/10.1016/S0736-0266(03)00110-4 — This investigation examined tendon structure, mechanical measurements, and cellular responses in animal and laboratory models.
• Sosne et al. (2002) — Thymosin Beta 4 Promotes Corneal Wound Healing and Decreases Inflammation In Vivo Following Alkali Injury. Experimental Eye Research. https://doi.org/10.1006/exer.2001.1125 — Researchers investigated changes in tissue restoration and inflammatory activity following experimentally induced corneal injury in mice.
• Linkova et al. (2023) — Peptide Regulation of Chondrogenic Stem Cell Differentiation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098415 — This scientific review discusses short peptides, including Cartalax (AED), in the study of cartilage-related cellular activity and differentiation. It is a review of experimental research, not a clinical trial of Cartalax.

Myakisheva et al. (2023) — The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative aging. Advances in Gerontology. Primary cell-culture study distinguishing the isolated AED peptide from a cartilage polypeptide complex. Supports Clinical Question 3; not evidence of joint benefits in people. https://pubmed.ncbi.nlm.nih.gov/37782646/

Understanding the Research Findings

The studies described above involve individual peptides investigated under different experimental conditions. Findings from animal experiments and laboratory studies cannot automatically be applied to human outcomes or to combinations of the compounds.

Although Cartalax, BPC-157, and Thymosin Beta-4 have each attracted research interest in tissue biology, the published findings do not establish synergistic activity, clinical effectiveness, or long-term safety for the Deadpool 30mg formulation.

Independent laboratory testing provides information about the identity, reported purity, and measured quantities of the submitted blend sample. These analytical results do not establish that the product produces the biological outcomes described in published studies.

House of Peptides' research product is not represented as clinically equivalent to materials evaluated in those investigations.

Research Use Notice

For laboratory research only. Not intended for human or veterinary administration, diagnostic, or therapeutic use.